AstraZeneca inks mRNA vaccine deal with China's CanSino
jetcityimage/iStock Editorial via Getty Images

Chinese vaccine maker CanSino Biologics (OTCPK:CASBF) announced Tuesday an agreement with AstraZeneca (NASDAQ:AZN) to provide "contract development and manufacturing services" for the Anglo-Swedish pharma giant's messenger RNA ((mRNA)) vaccine program.
Tianjin-based CanSino (OTCPK:CASBF) said it would produce and deliver unnamed mRNA products to AstraZeneca (AZN), Reuters reported, citing a regulatory filing the company submitted to the Shanghai Stock Exchange. The value of the deal is unclear.

AstraZeneca (AZN) didn't comment on the announcement, which comes on the heels of reports about a potential spinoff of the company's business in China.
AstraZeneca (AZN), the leading drugmaker in the country, was looking to spin off its operations there and seek a listing in Hong Kong in response to rising geopolitical tensions, the Financial Times reported in June.



More on AstraZeneca

AstraZeneca: Robust Performance And Promising Growth Initiatives
AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)
AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside
AstraZeneca, Sanofi RSV treatment Beyfortus endorsed by CDC panel (updated)
AstraZeneca-Ionis deal for eplontersen expands to Latin America